European Approval for Velcade as 2nd Line Treatment

Ortho Biotech today announced that the European Commission has approved the use of VELCADE® (bortezomib) for Injection as a second-line treatment in patients with multiple myeloma. It is indicated as monotherapy for use in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplantation. With today's announcement, more multiple myeloma patients can hope to receive earlier access to VELCADE® treatment.